Andrey M. Sheyanov

Andrey M. Sheyanov

Auto-generated profile, based on publicly available information

Andrey M. Sheyanov

Scientific Center for Mental Health, Moscow, Russia, I. M. Sechenov First Moscow State Medical University, Moscow, Russia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
DRDmitry Vladimirovich Romanov
Dmitry Vladimirovich Romanov
TNTatiana I. Nasonova
Tatiana I. Nasonova
AIAleksey I. Isaikin
Aleksey I. Isaikin
OFOlga V. Filileeva
Olga V. Filileeva
ASAndrey M. Sheyanov
Andrey M. Sheyanov
VPVladimir Parfenov
Vladimir Parfenov
Background: Evidence suggests that there is substantial comorbidity between fibromyalgia and Axis II pathology (i.e., personality disorders—PDs). The aim of the current study was to find out the exact cluster (A, B, C) of PDs or traits that are more prominent in FM and may be predictors of FM diagnosis. Methods: Data from 86 subjects (53 with FM and 33 controls without FM) were analyzed in an observational, cross-sectional, comparative study in a neurological setting. The assessment of categorical PDs and traits was performed independently with the Structured Clinical Interview for Personality Disorders (SCID-II). Binary logistic regression was used to determine FM predictors among PD traits. Results: Compared with controls, FM patients had a higher rate of PD diagnoses (56.7 vs. 18.2%, p < 0.001). However, the rate was significantly higher only for borderline PD diagnosis (28.3% vs. 6.1% p < 0.05). The binary logistic regression analysis showed that schizotypal and schizoid (cluster A), borderline (cluster B), and dependent (cluster C) personality traits may be significant predictors of fibromyalgia (Nagelkerke R2 = 0.415). Conclusions: Our results may reflect the association of FM with personality traits of all three PD clusters: A (eccentric), B (dramatic), and C (anxious). However, the most consistent evidence seems to be for borderline PD.

4 October 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
DRDmitry Vladimirovich Romanov
Dmitry Vladimirovich Romanov
TNTatiana I. Nasonova
Tatiana I. Nasonova
AIAleksey I. Isaikin
Aleksey I. Isaikin
OFOlga V. Filileeva
Olga V. Filileeva
ASAndrey M. Sheyanov
Andrey M. Sheyanov
VPVladimir Parfenov
Vladimir Parfenov
Background: Evidence suggests that there is substantial comorbidity between fibromyalgia and Axis II pathology (i.e., personality disorders - PDs). The aim of the current study was to find out the exact cluster (A, B, C) PDs or traits that are more prominent in FM and may be predictors of FM diagnosis. Methods: Data from 86 subjects (53 with FM and 33 controls without FM) was analyzed in an observational, cross-sectional, comparative study. The assessment of categorical PDs and traits was performed independently with the Structured Clinical Interview for Personality Disorders (SCID-II). Binary logistic regression was used to determine FM predictors among PDs traits. Results. Compared with controls, FM patients had higher rate of PDs diagnoses (56.7 vs 18.2%, P<.001). However, the rate was significantly higher only for borderline PD diagnosis (28.3% vs 6.1% P<.05). The binary logistic regression analysis showed that schizotypal and schizoid (cluster A), borderline (cluster B), and dependent (cluster C) personality traits may be significant predictors of fibromyalgia (Nagelkerke R2 = 0.415). Conclusions: Our results may reflect association of FM with personality traits of all three PD clusters: A (eccentric), B (dramatic), C (anxious). However, the most consistent evidence seems to be for borderline PD.

26 December 2023 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
DRDmitry Vladimirovich Romanov
Dmitry Vladimirovich Romanov
ASA.M. Sheyanov
A.M. Sheyanov
MSM D Samsonova
M D Samsonova
PIP.G. Iuzbashian
P.G. Iuzbashian
The purpose of this review is to correlate current data on the molecular mechanisms of action of the drug Nimodipine with its clinical effects and applicability in mental disorders belonging to the spectrum of affective pathology. The article discusses the prospects for using the calcium channel blocker nimodipine as a method of both mono and combination therapy for bipolar disorders with various types of course. Nimodipine is a selective blocker of voltage-dependent calcium channels, a dihydropyridine derivative. By blocking L type calcium channels, it prevents the entry of calcium ions into the cell. Due to its pronounced ability to penetrate the blood-brain barrier, it has a selective effect on brain neurons and has a vasodilating, antihypertensive and normotimic effect. Nimodipine blocks LTCC channels in brain neurons, thereby influencing synaptic plasticity, transmitter release and excitation-transcription coupling, which makes it possible to influence various clinical conditions with pathology in the area of affect, including bipolar disorders with ultra-rapid cycling, and also, in cases with high resistance and intolerance to other mood stabilizers.

21 May 2026 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Closed access
VIVladimir Ivashkin
Vladimir Ivashkin
Maria LivzanMaria Livzan
Maria Livzan
DAD. I. Abdulganieva
D. I. Abdulganieva
OAO. P. Alexeeva
O. P. Alexeeva
SAS. A. Alekseenko
S. A. Alekseenko
AUA. I. Ulyanin
A. I. Ulyanin
Aim : to review current understanding of the role of intestinal microbiota in the pathogenesis of irritable bowel syndrome (IBS), anxiety and depressive disorders, and to present the materials of the Expert Council, which met on April 19, 2025, in Moscow. Key points. A likely unifying factor in the development of IBS, anxiety, and depressive disorders is a change in the composition of the intestinal microbiota, which causes disruption of neuroendocrine, immune, and metabolic signaling pathways of interaction between the gut and brain (components of the gut-brain axis). The intestinal microbiota plays a coordinating role in maintaining the physiological constancy of these pathways. However, when its composition is disrupted, pathogenic mechanisms are activated, leading to the combined development of both IBS and anxiety and depressive disorders. Recent data have shown that patients with IBS, as well as those suffering from anxiety and depressive disorders, exhibit a unidirectional change in the composition of the intestinal microbiota, characterized by a decrease in the number of Bifidobacterium bacteria , suggesting their key role in the pathogenesis of these diseases. A pathogenetically substantiated therapeutic strategy for the combination of IBS and mental disorders includes modifying the gut microbiota using strain-specific pro biotics containing Bifidobacterium type species. Bifidobacterium longum 35624 and Bifidobacterium longum 1714 strains have demonstrated clinical efficacy in reducing the severity of IBS symptoms, anxiety, and depression. Conclusion . Prescribing a combination of Bifidobacterium longum 35624 and Bifidobacterium longum 1714 probiotic strains to patients with IBS, including those with comorbid mental disorders, is clinically justified. This combination of strains holds promise for inclusion in clinical guidelines for the management of patients with irritable bowel syndrome and mental and behavioral disorders.

20 November 2025 in Лечащий врач
Verified
Journal Article
Open access
PDF file
DRDmitry Vladimirovich Romanov
Dmitry Vladimirovich Romanov
ASA.M. Sheyanov
A.M. Sheyanov
ЕВЕ. И. Воронова
Е. И. Воронова
AMA.V. Michenko
A.V. Michenko
ALAndrey Lvov
Andrey Lvov
Background. Hypochondriasis, including that with an affinity for the skin, remains a serious diagnostic and treatment challenge. As the outer boundary of the body, the skin is involved in the formation of psychopathological perception disorders. With its obvious ability to quickly heal itself and its accessibility, unlike internal organs, the skin can often become the target of self-harm in a number of self-destructive disorders (neurotic excoriations, artificial dermatitis, etc.). As an integral component of appearance, the skin becomes part of the clinical manifestations of mental disorders related to body image pathology.The publication provides an analysis of both theoretical and practical aspects of the problem based on a model of non-delusional hypochondriasis with presentations of somatoform and obsessive itch, skin health anxiety, and cutaneous autonomic dysfunction ("skin organ neurosis"). Materials and methods. Analysis of the main scientific concepts of non-delusional hypochondriasis, related to skin; description of a clinical case, i.e. a patient with "skin organ neurosis"; evaluation of the results of therapy with Alimemazine supplemented by a psychotherapeutic intervention. Results. The ambiguity of the clinical qualification of non-delusional hypochondriasis in relation to disorders in dermatology is shown; a dimensional model of non-delusional hypochondriasis extending previous concepts is proposed; the model includs the intersection of several psychopathological axes; the provisions of the proposed model are illustrated by the clinical case; the high effectiveness of alimemazine in relation to symptoms derived from various psychopathological dimensions is demonstrated. Conclusions. The set of clinical phenomena labeled in the literature by the term "non-delusional hypochondriasis" is a multidisciplinary construct that includes associated coenesthetic, personality and ideatory (anxious and obsessive) hypochondriac phenomena characterized by a differentiated response to psychopharmacologic intervention and psychotherapy.

6 October 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
VRV.A. Rozhdestvenskaya
V.A. Rozhdestvenskaya
PYP.G. Yuzbashyan
P.G. Yuzbashyan
DRDmitry Vladimirovich Romanov
Dmitry Vladimirovich Romanov
ASA.V. Shchurenkov
A.V. Shchurenkov
PKP.A. Kazaryan
P.A. Kazaryan
IFI.K. Fedyainova
I.K. Fedyainova
Semaglutide is a glucagon-like peptide-1 receptor agonist, approved and currently actively used worldwide for the treatment of type 2 diabetes mellitus and obesity. With the growing popularity of the drug, reports of both adverse and beneficial effects of the drug on mental health have become more frequent. The purpose of this study is to review the impact of semaglutide on mental health by collecting, analyzing, and synthesizing current scientific evidence. The authors conclude that currently there is no unequivocal opinion on this matter, which opens up new horizons for future research.